Regeneron Says Its Antibody Cocktail Likely Weakened by Omicron Variant
TUESDAY, Nov. 30, 2021 (HealthDay News) -- Regeneron Pharmaceuticals said Tuesday that its antibody cocktail, which is used widely to treat COVID-19 patients, may be less effective against the Omicron variant.
The company noted that prior analyses suggest that its monoclonal antibody cocktail, and similar drugs, could lose effectiveness against the variant.
Further research is ongoing, according to Regeneron, which added there is no direct data yet testing the new variant's resistance to immunity from monoclonal antibodies and vaccines. The company did note that it is already testing the next generation of antibody treatments that might show greater potency against the Omicron variant.
Health officials consider monoclonal antibodies highly effective in preventing hospitalization among patients with mild to moderate COVID-19 if the therapy is given within seven to 10 days after symptoms appear.
The treatment -- typically administered through four injections or a half-hour infusion -- provides antibodies that quickly target the coronavirus while the body's immune system gears up to fight it, the Washington Post reported.
President Donald Trump was given Regeneron's antibody cocktail when he was infected with the virus in 2020. It is now widely available to the American public.
More information
Visit the U.S. National Institutes of Health for more on COVID antibody treatments.
Related Articles
Search Allergy Articles
What Is Chronic Sinusitis, and How Is it Treated?
Ragweed, Mold & More: Get Ready for Fall Allergies
Back-to-School Tips on Preventing Asthma, Allergy Flares in Kids
FDA Expands Use of Asthma Med Xolair to Treat Food Allergies
First Asthma-Linked Death Highlights Hazards at Marijuana-Processing Plants
Gas Stoves Could Leave Your Lungs Vulnerable to Nitrogen Dioxide
It's Time to Start Preparing Against Flu, RSV & COVID-19
Could Antibody Discovery Lead to Better Flu Vaccines?
Contrary to Popular Belief, 1918 Flu Did Not Target the Healthy Young
Flu May Be Tougher on Brain Health Than COVID-19: Study
Respiratory Illnesses in China Not Caused by New Virus, CDC Director Testifies